A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00158093|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : September 12, 2005
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: Nebivolol Drug: Atenolol Drug: Moxifloxacin||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||260 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Parallel Group Safety Evaluation of Electrocardiographic Intervals and Blood Pressure in Normal Healthy Volunteers After Nebivolol, Atenolol, Moxifloxacin, or Placebo Administration After Single and Repeated Doses|
|Study Start Date :||June 2003|
|Study Completion Date :||July 2003|
- The primary study endpoint was the change in the average QTc intervals from Day 0 to 2 hours after dosing on Day 7.
- The secondary endpoints were the change in average QTc intervals from Day 0 to all other evaluation times and the change in other ECG intervals (PR, RR, QRS, QT) and HR from Day 0 to all other evaluation times.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Men and nonpregnant, nonlactating women were 18 years or older.
- Women declaring postmenopausal or surgical sterility.
- Women of childbearing potential who had a negative serum HCG within 2 weeks of dosing.
- Male subjects weighed at least 60 kg (132 lb), and female subjects weighed at least 48 kg (106 lb). All volunteers weighed within 15% of their ideal body weight (IBW).
Reported or was known to have done the following:
- Used any tobacco product.
- Ingested any alcoholic, caffeine or xanthine containing food or beverage within the 48 hours prior to the initial dose of study medication
- Consumed grapefruit or grapefruit containing products within 7 days prior to the initial dose of study medication.
- Ingested any vitamins or herbal products within the 48 hours prior to the initial dose of study medication.
- Recently changed dietary or exercise habits significantly
- Used any medication (including over-the-counter [OTC]) within the 14 days prior to the initial dose of study medication.
- Used any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.
- Received an investigational drug within 30 days prior to the initial dose of study medication.
- History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease.
- History of drug and/or alcohol abuse within 1 year prior to the study.
- Acute illness at the time of either the pre study medical evaluation or dosing.
- Any laboratory results deemed clinically significant by the physician.
- Abnormal and clinically relevant ECG tracing.
- Donated or lost a significant volume of blood or plasma (>450 mL) within 28 days prior to the initial dose of study medication.
- Allergic or hypersensitive to nebivolol, atenolol, or other β blocking drugs or to moxifloxacin or other quinolone antibiotics.
- History of seizures or cerebrovascular disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00158093
|United States, Florida|
|SFBC International, Inc.|
|Miami, Florida, United States, 33181|
|Principal Investigator:||Lawrence A Galitz, MD||SFBC International|
|Study Director:||Will A Sullivan, BS||Mylan Bertek Pharmaceuticals Inc.|
|Other Study ID Numbers:||
|First Posted:||September 12, 2005 Key Record Dates|
|Last Update Posted:||September 12, 2005|
|Last Verified:||September 2005|
Topoisomerase II Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-1 Receptor Agonists